Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study

Cephalalgia

Volumn 16, Issue 7, 1996, Pages 497-502

  Goldstein, J ^a   Dahlof C G H ^b   Diener, H C ^h   Olesen, J ^c   Schellens, R ^d   Senard, J M ^e   Simard, D ^f   Steiner, T J ^g  

^a San Francisco Headache Clinic   (United States)

^b Göteborgs Migränklinik   (Sweden)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f LAVAL UNIVERSITY   (Canada)

^g Princess Margaret Migraine Clinic   (United Kingdom)

^h NONE

Author keywords

Alniditan; Dose finding study; Migraine; Placebo; Randomized controlled trial

Indexed keywords

ALNIDITAN; SEROTONIN AGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BENZOPYRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PROPYLAMINES; PYRIMIDINES; SEROTONIN AGONISTS; VASOCONSTRICTOR AGENTS;

EID: 0029839252     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1996.1607497.x     Document Type: Article

References (17)

1. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-51
2. Dechant KL, Clissold SP. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43:776-98
3. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993;13:151-65
4. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
5. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21
6. The Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with Subcutaneous sumatriptan using an auto-injector device. Eur Neurol 1991;31:323-31
7. Bousser MG, D'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med 1993;234:211-6
8. Humphrey PPA, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401-10
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988;8 Suppl 7:9-96
10. Lippert J, Lehmann A. SI units in medicine. Baltimore/ Munich: Urben and Schwarzenberg, 1978
11. 1D agonists. Bioorganic Med Chem Lett 1995;22:2649-54
12. Wilkinson M, Pfaffenrath V, Schoenen J, Diener H-C, Steiner TJ. Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-57
13. Mushet GR, Clements B. Efficacy of subcutaneous sumatriptan administration by a novel autoinjector device. Headache 1992;32:255
14. Henry P, D'Allens H and the French Migraine Network Bordeaux-Lyon-Grenoble. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache 1993;33:432-5
15. Klein KB. 311C90, a new acute treatment for migraine: an efficacy overview. Proceedings of the 7th International Headache Congress, Toronto, Canada, September 16-20, 1995. Cephalalgia 1995;15; Suppl 14.
16. 1D receptor agonists in development. Proceedings of the 6th International Headache Research Seminar, Copenhagen, Denmark, November 17-19, 1995
17. Ferrari MD, Haan J. Acute treatment of migraine attacks. Curr Opin Neurol 1995;8:237-42